ISLAMABAD, July 13 (online): We track the progress of a newly developed vaccine, examine the benefits of repurposing existing vaccines, and see how a synthetic antibody can “distract” and neutralize the new coronavirus before it reaches healthy cells.
The recombinant vaccine that the team developed uses a chimpanzee adenovirus (called ChAdOx1) that is harmless to humans, inserting into it the spike protein gene of SARS-CoV-2.
As this approach to developing vaccines has been “extensively tested in other situations,” and the research group has a successful track record in this area (which includes developing a promising vaccine against MERS, a “cousin” of SARS), experts were hopeful a few months ago.
The Jenner Institute have tested the vaccine, called the ChAdOx1 nCoV-19 vaccine, in pigs and found that two doses create a greater antibody response than one dose.
Phase I of the human clinical trials has already started. The researchers are testing a single dose of ChAdOx1 nCoV-19 because research in macaque monkeys showed that a single immunization with the vaccine protected against lung disease.
Stay tuned to BAAGHI TV for latest news and updates!